Korean Circ J.  2011 Sep;41(9):546-548. 10.4070/kcj.2011.41.9.546.

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction

• Choi WG
• Oh SW
• Kim YJ
• Lim JG
• Jo YS

• KMID: 2094108
• DOI: http://doi.org/10.4070/kcj.2011.41.9.546

Abstract

Stroke is a rare but serious complication of acute myocardial infarction (AMI). Currently, glycoprotein (GP) IIb/IIIa inhibitor is used in clinical practice for acute coronary syndromes and percutaneous coronary interventions (PCIs). The incidence of stroke in patients receiving GP IIb/IIIa inhibitor during PCIs is very low. We report the case of a 47-year-old man who presented with AMI and suffered an acute cerebral infarction after infusion of a GP IIb/IIIa inhibitor following primary PCI.

Keyword

Myocardial infarction; Acute stroke; Platelet glycoprotein GP IIb-IIIa complex

MeSH Terms

Acute Coronary Syndrome
Cerebral Infarction
Glycoproteins
Humans
Incidence
Middle Aged
Myocardial Infarction
Percutaneous Coronary Intervention
Stroke
Glycoproteins

Figure

• 

  Fig. 1 Twelve lead electrocardiography shows ST segment elevation in lead II, III, and aVF.

• 

  Fig. 2 Coronary angiogram reveals total occlusion of distal right coronary artery with a large occlusive thrombus.

• 

  Fig. 3 Coronary angiogram after stent implantation demonstrates adequate luminal diameter of distal right coronary artery but residual thrombus.

• 

  Fig. 4 Brain magnetic resonance scan reveals acute ischemic infarction in the right middle cerebral artery territory after glycoprotein IIb/IIIa inhibitor infusion. A diffusion-weighted image reveals a region of hyperintensity in the distribution of the right middle cerebral artery (A). A T2-weighted image demonstrates a high signal intensity in the territory of the right middle cerebral artery (B).

Reference

1. Hess DC, D'Cruz IA, Adams RJ, Nichols FT 3rd. Coronary artery disease, myocardial infarction, and brain embolism. Neurol Clin. 1993. 11:399–417.

2. Komrad MS, Coffey CE, Coffey KS, McKinnis R, Massey EW, Califf RM. Myocardial infarction and stroke. Neurology. 1984. 34:1403–1409.

3. Akkerhuis KM, Deckers JW, Lincoff AM, et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA. 2001. 286:78–82.

4. Mooe T, Olofsson BO, Stegmayr B, Eriksson P. Ischemic stroke: impact of a recent myocardial infarction. Stroke. 1999. 30:997–1001.

5. Behar S, Tanne D, Abinader E, et al. Cerebrovascular accident complicating acute myocardial infarction: incidence, clinical significance and short- and long-term mortality rates. Am J Med. 1991. 91:45–50.

6. Torgano G, Zecca B, Monzani V, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. Cerebrovasc Dis. 2010. 29:275–281.

7. Oh YJ, Park TH, Choi YJ, et al. Abciximab (ReoPro)-induced thrombocytopenia diagnosed through measurement of heparin-dependent antibody. Korean Circ J. 2009. 39:75–78.

8. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J. 1995. 130:877–892.

9. Chang GY. An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction. Eur J Neurol. 2001. 8:267–268.